CARMIEL, Israel--(BUSINESS WIRE)--Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Company will host an Analyst and Investor Event on December 1, 2009 from 5:00 to 7:00 p.m. ET in New York City. Dr. David Aviezer, President and CEO of Protalix Biotherapeutics, and David Simmons, President and General Manager, Established Products Business Unit, Pfizer Inc, will discuss the recently announced collaboration for taliglucerase alfa for the treatment of Gaucher disease.
